Pfizer buys Seagen for $43 Billion, boosts access to cancer drugs
Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue.
Stay updated with breaking news from Array Biopharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue.
Pfizer is spending about US$43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue.
<div class="at-above-post addthis_tool" data-url="https://www.metro.us/pfizer-buys-seagen-for-43b-boosts-access-to-cancer-drugs/"></div>Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue. The pharmaceutical giant said Monday it will pay $229 in cash for each share of Seagen Inc. Pfizer then plans to let the biotech drug developer “continue innovating,” except with more resources than […]<!-- AddThis Advanced Settings above via filter on get_the_excerpt --&...
Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue.
The pharmaceutical giant says it will pay $229 in cash for each share of Seagen.